News IFB-Logo-Green-700×237 Home > InFlectis BioScience receives approval from the French regulatory authority to conduct a phase 2 clinical trial for IFB-088 (Icerguastat) for the treatment of Amyotrophic Lateral Sclerosis > IFB-Logo-Green-700×237 28 May 2021
